pyrroles has been researched along with Carcinoma in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (7.69) | 18.7374 |
| 1990's | 1 (1.92) | 18.2507 |
| 2000's | 15 (28.85) | 29.6817 |
| 2010's | 25 (48.08) | 24.3611 |
| 2020's | 7 (13.46) | 2.80 |
| Authors | Studies |
|---|---|
| Brawner, W; Ehling, TJ; Farrelly, J; Fidel, J; Green, E; Haney, S; Klein, MK; LaDue, T; Looper, J; Prescott, D; Saba, C; Shiomitsu, K; Smith, L; Turek, M | 1 |
| Goto, S; Iwasaki, R; Maeda, A; Mori, T; Murakami, M; Sakai, H; Yamada, K | 1 |
| Barber, LG; Keyerleber, MA | 1 |
| Chen, J; Huang, XR; Lan, HY; Lee, CS; Li, M; Lian, GY; Mak, TS; Tang, PM; Wan, Y; Wang, QM; Wang, ZY; Yu, XQ; Zhang, J | 1 |
| Chen, L; Chen, S; Wang, Q; Yang, HS; Zhang, Y; Zheng, H; Zhu, J | 1 |
| Al-Obaidy, KI; Cheng, L | 1 |
| Borrego, JF; Clemente-Vicario, F; Hernández, A; Merino-Gutierrez, V; Puig, J | 1 |
| Jin, Y; Ma, X; Meng, H; Tian, J; Xu, M; Xu, W; Yang, X; Zhang, S | 1 |
| Chen, XT; Guo, KY; He, YJ; Huang, YX; Li, YH; Song, CY; Wu, BY | 1 |
| Henningson, J; Higginbotham, ML; Hocker, SE; Schermerhorn, T | 1 |
| Boudreaux, BB; Dedeaux, AM; Langohr, IM | 1 |
| Cámara-Fernández, N; Cartagena-Albertus, JC; Moise, A; Montoya-Alonso, JA; Moya-García, S | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Alonso, T; Díez, JJ; Grande, E; Iglesias, P | 1 |
| Huang, J; Ma, J; Mu, X; Qin, Y; Wu, G; Xu, S; Yang, K; Zhang, Z; Zhou, H | 1 |
| Barett, C; Bikas, A; Burman, KD; Clark, BG; Desale, S; Gandhi, R; Jelinek, JS; Kundra, P; Mete, M; O'Keefe, K; Wartofsky, L; Wexler, JA; Wray, L | 1 |
| Ding, L; Meng, X; Song, S; Sun, B; Wu, S; Zhao, X | 1 |
| Chang, CC; Chang, Y; Cheung, MW; Ho, C; Huang, CP; Lee, WC; Lin, WC; Or, CR; Su, HL | 1 |
| Asselineau, J; Bournaud-Salinas, C; Caron, P; Catargi, B; Daste, A; de la Fouchardière, C; Delord, JP; Digue, L; Do Cao, C; Doussau, A; Gimbert, A; Klein, M; Nicolli-Sire, P; Pedenon, D; Picat, MQ; Pouessel, D; Ravaud, A; Rodien, P; Wemeau, JL | 1 |
| Bang, SM; Kim, CJ; Kim, H; Kim, JH; Kim, JS; Kim, YJ; Lee, HE; Lee, JO; Lee, JS; Lee, KW | 1 |
| Bellmunt, J; Calvo, E; Castellano, D; Climent, MA; Esteban, E; García del Muro, X; González-Larriba, JL; Maroto, P; Trigo, JM | 1 |
| Calderan, L; Daducci, A; Degrassi, A; Farace, P; Galiè, M; Marzola, P; Merigo, F; Nicolato, E; Pesenti, E; Sbarbati, A | 1 |
| Bovée, JV; Gelderblom, H; Hogendoorn, PC; Kroep, JR; van der Molen, AJ | 1 |
| Burstein, HJ; Dhakil, S; Fabian, C; Kozloff, M; Mayer, EL; Parmar, H; Patel, T; Qamar, R; Samant, M; Sundaram, S; Volterra, F | 1 |
| Fisher, C; Fisher, R; Gore, M; Larkin, J; Livni, N; Pickering, L; Thway, K | 1 |
| Bauman, JE; Capell, PT; Carr, LL; Eaton, KD; Goulart, BH; Kell, EM; Mankoff, DA; Martins, RG | 1 |
| Ahuja, AT; Chan, ATC; Chan, SL; Hui, EP; Kam, MKM; King, AD; Loong, HH; Ma, BBY; Mo, F; Zee, BCY | 1 |
| Deutsch, E; Soria, JC | 1 |
| Canipari, C; Chen, K; Duh, MS; Imarisio, I; Neary, M; Paglino, C; Porta, C | 1 |
| Brufsky, AM; Copur, MS; Davis, J; Generali, D; Gernhardt, D; Giguere, JK; Gressot, L; Huang, X; Kern, KA; Liau, KF; Minton, SE; Paul, D; Richards, PD; Robert, NJ; Saleh, MN; Smith, JW | 1 |
| Ahn, SH; An, SY; Choi, IJ; Jeon, EH; Jeong, WJ; Mo, JH; Park, MW | 1 |
| Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A | 1 |
| Alvarez, F; Beaver, L; Bryan, J; Carreras, J; Clifford, C; Ettinger, S; Fulton, L; Gauthier, M; Gill, V; Gillings, S; Haney, S; Henry, C; Hershey, B; Higginbotham, ML; Hillman, L; Jones, P; Kiselow, M; Klein, MK; Krick, E; Ladue, T; London, C; Mathie, T; McNeill, C; Novasad, A; Phillips, B; Stingle, N; Thamm, D; Vail, DM; Vaughan, A; Vickery, K | 1 |
| Boni, G; Ferdeghini, M; Mariani, G; Monzani, F; Pasqualetti, G; Polini, A; Ricci, S; Tognini, S | 1 |
| Kisseberth, WC; London, CA; Russell, DS; Urie, BK | 1 |
| Cai, Z; Chen, W; Jin, Q; Ye, X | 1 |
| Li, QQ; Reed, E; Zhong, X | 1 |
| Bair, EL; Bowden, GT; Nagle, RB; Udayakumar, TS | 1 |
| Baldwin, SJ; Kotyk, JJ; Pagel, MD; Rader, RK | 1 |
| Abbruzzese, JL; Bogaard, K; Hoff, PM; Waldrum, S; Wolff, RA | 1 |
| Ajith, TA; Soja, M | 1 |
| Kamaike, K; Kashiwagi, K; Kawashima, E; Nakanishi, Y; Ohba, Y; Terui, Y; Tomitori, H | 1 |
| Basch, E; Motzer, RJ | 1 |
| Barbosa, S; Barrish, JC; Bhide, RS; Borzilleri, RM; Cai, ZW; D'Arienzo, C; Derbin, G; Fan, J; Fargnoli, J; Hunt, JT; Jeyaseelan, R; Kamath, A; Kukral, DW; Lombardo, LJ; Marathe, P; Mortillo, S; Qian, L; Robl, JA; Shi, Z; Wautlet, BS; Wei, D; Wu, L; Zhang, Y; Zheng, X | 1 |
| Adams, BJ; Baum, CM; Bello, CL; Burstein, HJ; Cobleigh, MA; DePrimo, SE; Eisenberg, PD; Elias, AD; Lehman, M; Miller, KD; Rugo, HS; Wolff, AC | 1 |
| Galski, H; Gottesman, MM; Hochman, J; Lazarovici, P; Matsuda, Y; Murakata, C | 1 |
| Asai, A; Ashizawa, T; Kakita, S; Mihara, A; Mizukami, T; Nakano, H; Ochiai, K; Ogawa, H; Sakai, Y; Yamashita, Y | 1 |
| Campiani, G; Hyland, E; Mc Gee, MM; Nacci, V; Ramunno, A; Zisterer, DM | 1 |
| Artico, M; De Martino, G; Dolfini, E; Giuliano, R; Massa, S; Morasca, L; Porretta, GC | 1 |
| Artico, M; Chimenti, F; Dolfini, E; Giuliano, R; Morasca, L; Vomero, S | 1 |
| Phillips, DM; Phillips, SG | 1 |
| Bhuyan, BK; Li, LH; Neil, GL; Olin, EJ; Smith, CG | 1 |
2 review(s) available for pyrroles and Carcinoma
| Article | Year |
|---|---|
Fibroblast growth factor receptor (
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Exons; Gene Amplification; Gene Fusion; Genetic Predisposition to Disease; Humans; Molecular Targeted Therapy; Mutation, Missense; Phenotype; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms; Urothelium | 2021 |
Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Liver Neoplasms; Piperazines; Pyrimidines; Pyrroles; Soft Tissue Neoplasms; Subcutaneous Fat; Sunitinib | 2009 |
10 trial(s) available for pyrroles and Carcinoma
| Article | Year |
|---|---|
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Iodine Radioisotopes; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Pyrroles; Radiotherapy; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Pyrroles; Sunitinib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome | 2017 |
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Cell Differentiation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Pyrroles; Sunitinib; Thyroid Neoplasms; Tomography, Emission-Computed; Treatment Failure | 2010 |
Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Epistaxis; Female; Hematemesis; Hemoptysis; Humans; Indoles; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome | 2011 |
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Lung Neoplasms; Male; Melanoma; Middle Aged; Pancreatic Neoplasms; Proteasome Inhibitors; Pyrroles; Vorinostat | 2012 |
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Treatment Outcome | 2006 |
Targeted drugs for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma; Costs and Cost Analysis; Double-Blind Method; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Pyrroles; Recombinant Proteins; Sirolimus; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A | 2007 |
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Survival Rate; Taxoids | 2008 |
40 other study(ies) available for pyrroles and Carcinoma
| Article | Year |
|---|---|
A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma; Dog Diseases; Dogs; Indoles; Nose Neoplasms; Prospective Studies; Pyrroles | 2022 |
Outcome of Localized Bile Duct Carcinoma in Six Dogs Treated with Liver Lobectomy.
Topics: Animals; Bile Ducts; Carcinoma; Dog Diseases; Dogs; Liver; Pyrroles | 2022 |
Pilot study evaluating the tolerability of a 3 Gy × 10 daily fraction 3D-conformal palliative radiation therapy protocol plus toceranib for the treatment of measurable carcinomas in the dog.
Topics: Animals; Carcinoma; Dog Diseases; Dogs; Pilot Projects; Prospective Studies; Pyrroles; Quality of Life; Radiotherapy, Conformal | 2022 |
Self-carried nanodrug (SCND-SIS3): A targeted therapy for lung cancer with superior biocompatibility and immune boosting effects.
Topics: Animals; Carcinoma; Cell Line, Tumor; Isoquinolines; Lung Neoplasms; Mice; Nanoparticles; Pyridines; Pyrroles; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta | 2022 |
IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
Topics: Animals; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Kinase 1; Mice; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Triazines; Xenograft Model Antitumor Assays | 2020 |
Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020).
Topics: Animals; Antineoplastic Agents; Carcinoma; Dog Diseases; Dogs; Indoles; Nose Neoplasms; Pyrroles; Retrospective Studies | 2021 |
A tantalum oxide-based core/shell nanoparticle for triple-modality image-guided chemo-thermal synergetic therapy of esophageal carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma; Cell Line, Tumor; Contrast Media; Doxorubicin; Drug Carriers; Drug Liberation; Esophageal Neoplasms; Fluorescent Dyes; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen-Ion Concentration; Male; Mice, Inbred BALB C; Multimodal Imaging; Nanoparticles; Optical Imaging; Oxides; Photoacoustic Techniques; Phototherapy; Polymers; Predictive Value of Tests; Pyrroles; Solubility; Tantalum; Temperature; Theranostic Nanomedicine; Time Factors; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2017 |
Sunitinib Induces NK-κB-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Coculture Techniques; Combined Modality Therapy; Cytotoxicity, Immunologic; Gene Expression; Hep G2 Cells; Humans; Immunologic Surveillance; Immunotherapy, Adoptive; Indoles; Killer Cells, Natural; Ligands; Liver Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; NF-kappa B; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Pyrroles; RNA, Small Interfering; Signal Transduction; Sunitinib | 2017 |
Receptor tyrosine kinase expression and phosphorylation in canine nasal carcinoma.
Topics: Animals; Carcinoma; Dogs; Gene Expression Regulation, Enzymologic; Humans; Immunohistochemistry; Indoles; Nose Neoplasms; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Tissue Culture Techniques | 2017 |
Long-term clinical control of feline pancreatic carcinoma with toceranib phosphate.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cat Diseases; Cats; Female; Indoles; Pancreatic Neoplasms; Pyrroles | 2018 |
Presumptive primary intrathoracic mast cell tumours in two dogs.
Topics: Animals; Antineoplastic Agents; Carcinoma; Dog Diseases; Dogs; Female; Indoles; Lung Neoplasms; Mast Cells; Pyrroles; Thoracic Neoplasms; Thoracic Wall | 2019 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Thyroglobulin; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2015 |
Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation.
Topics: Animals; Carcinoma; Cell Line, Tumor; Female; Humans; Indoles; Mice; Mice, Nude; Microvessels; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Radiation Tolerance; Receptor, Platelet-Derived Growth Factor beta; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Salvage Therapy; Sunitinib; Treatment Outcome; Ulcer | 2016 |
Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells.
Topics: Carcinoma; Cell Proliferation; Colorectal Neoplasms; Cyclin D1; Down-Regulation; G1 Phase Cell Cycle Checkpoints; HCT116 Cells; HT29 Cells; Humans; Indoles; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2016 |
Metastatic adrenocortical carcinoma treated with sunitinib: a case report.
Topics: Adrenal Cortex Neoplasms; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Resistance, Neoplasm; Humans; Indoles; Male; Mitotane; Pyrroles; Radiotherapy, Adjuvant; Sunitinib; Treatment Failure; Treatment Outcome; Young Adult | 2009 |
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Linear Models; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors | 2009 |
Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas.
Topics: Animals; Carcinoma; Cell Proliferation; Colonic Neoplasms; Disease Progression; HT29 Cells; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases; Stromal Cells; Up-Regulation; Xenograft Model Antitumor Assays | 2009 |
Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Carcinoma; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2010 |
Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?
Topics: Antineoplastic Agents; Carcinoma; Female; Hematemesis; Hemoptysis; Humans; Indoles; Male; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrroles; Sunitinib | 2011 |
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Fatigue; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Oncology Service, Hospital; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
Topics: Animals; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; MAP Kinase Kinase Kinases; Mice; Mutation; Nuclear Proteins; Proto-Oncogene Proteins B-raf; Pyrroles; raf Kinases; Signal Transduction; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
Topics: Adenocarcinoma; Anal Gland Neoplasms; Anal Sacs; Animals; Antineoplastic Agents; Apocrine Glands; Bone Neoplasms; Carcinoma; Dog Diseases; Dogs; Female; Head and Neck Neoplasms; Indoles; Male; Neoplasms; Nose Neoplasms; Osteosarcoma; Pyrroles; Receptor Protein-Tyrosine Kinases; Skin Neoplasms; Thyroid Neoplasms | 2012 |
Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Off-Label Use; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2012 |
Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma.
Topics: Anal Gland Neoplasms; Anal Sacs; Animals; Carcinoma; Dog Diseases; Dogs; Female; Gene Expression Regulation, Neoplastic; Indoles; Male; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-ret; Pyrroles; Receptors, Platelet-Derived Growth Factor; RNA, Messenger; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
[The effect and mechanism of SU11248 on proliferation of nasopharyngeal carcinoma cell line CNE-2].
Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cyclin G1; Cyclin-Dependent Kinase Inhibitor p27; Gene Expression Regulation, Neoplastic; Humans; Indoles; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrroles; RNA, Messenger; Sunitinib | 2013 |
SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair.
Topics: Carcinoma; Cisplatin; DNA Damage; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Indoles; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Proteins; Proto-Oncogene Proteins c-jun; Pyrroles; Transcription Factor AP-1; Tumor Cells, Cultured | 2003 |
Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression.
Topics: Animals; Carcinoma; Enzyme Precursors; Humans; Male; Metalloendopeptidases; Mice; Mice, Nude; Neoplasm Transplantation; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Receptors, Fibroblast Growth Factor; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Assessment of anti-metastatic drug efficacy via localization and quantification of ex vivo murine bone tumor load using high-throughput MRI T1 parametric analysis.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Prognosis; Pyrroles; Sunitinib; Treatment Outcome | 2006 |
A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagens.
Topics: Anticarcinogenic Agents; Antimutagenic Agents; Atorvastatin; Carcinoma; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Lovastatin; Mutagenesis; Mutagenicity Tests; Mutagens; Mutation; Pyrroles; Salmonella; Salmonella typhimurium | 2006 |
Synthesis and evaluation of 2-pyrrolepolyamide-2'-deoxyguanosine 5'-phosphate.
Topics: Animals; Antineoplastic Agents; Carcinoma; Guanosine Monophosphate; Mammary Neoplasms, Experimental; Mice; Pyrroles | 2007 |
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth fa
Topics: Administration, Oral; Alanine; Animals; Biological Availability; Carcinoma; Cell Proliferation; Clinical Trials, Phase II as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Intestines; Liver; Lung Neoplasms; Mice; Microsomes; Molecular Structure; Prodrugs; Protein Kinase Inhibitors; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Solubility; Stereoisomerism; Triazines; Vascular Endothelial Growth Factor Receptor-2; Water; Xenograft Model Antitumor Assays | 2008 |
KT-5720 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human MDR1 cDNA and in human multidrug-resistant carcinoma cells.
Topics: Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Southern; Carbazoles; Carcinoma; DNA, Complementary; Drug Resistance, Multiple; Humans; Indoles; Lymphoma; Mice; Protein Kinase C; Pyrroles; Transduction, Genetic; Tumor Cells, Cultured | 1995 |
Pyrronamycin A and B, novel antitumor antibiotics containing pyrrole-amide repeating unit, produced by Streptomyces sp.
Topics: Animals; Antibiotics, Antineoplastic; Antiviral Agents; Carcinoma; Distamycins; Fermentation; Humans; Lung Neoplasms; Mice; Mice, Nude; Microbial Sensitivity Tests; Pyrroles; Sarcoma 180; Streptomyces; Structure-Activity Relationship | 2000 |
Caspase-3 is not essential for DNA fragmentation in MCF-7 cells during apoptosis induced by the pyrrolo-1,5-benzoxazepine, PBOX-6.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Caspase 3; Caspase 7; Caspases; DNA Fragmentation; Enzyme Activation; Female; Flow Cytometry; Humans; In Situ Nick-End Labeling; Oxazepines; Pyrroles; Tumor Cells, Cultured | 2002 |
[Research and substances with antineoplastic activity. 48. Anthramycin and analogue compounds. 3. Synthesis and cytostatic activity of derivatives of 10,11-dihydro-5H-pyrrolo(2,1)(1,4)-benzodiazepine-3-carboxyaldehyde].
Topics: Acrylamides; Aldehydes; Antibiotics, Antineoplastic; Benzazepines; Carboxylic Acids; Carcinoma; Cell Line; Cells, Cultured; Humans; Male; Mouth Neoplasms; Pyrroles; Spectrophotometry, Infrared; Structure-Activity Relationship | 1972 |
[Research on antineoplastic substances. LI. Derivatives of benzo(f)-pyrrolo-(1,2-a)-quinoxaline and naphtho-(2,1-e)-pyrrolo-(2,1-c)-as-triazine: synthesis and cytostatic and cytotoxic activity].
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line; Cells, Cultured; Culture Media; Humans; Mouth Neoplasms; Nasopharyngeal Neoplasms; Pyrroles; Quinoxalines; Structure-Activity Relationship; Triazines | 1973 |
Distinctive characteristics of nucleoli of two established cell lines.
Topics: Animals; Antibiotics, Antineoplastic; Autoradiography; Carcinoma; Cell Line; Cell Nucleolus; Connective Tissue; Culture Techniques; Cytoplasm; Dactinomycin; Histocytochemistry; Humans; L Cells; Mice; Mouth Neoplasms; Pyrimidines; Pyrroles; Ribose; RNA; RNA, Ribosomal; Skin; Time Factors; Tritium; Uridine | 1971 |
Biological and biochemical differences between tubercidin (7-deazaadenosine) and its 5'-phosphate methyl ester.
Topics: Animals; Antineoplastic Agents; Blood; Carcinoma; Cell Line; Chromatography, Paper; Culture Media; Depression, Chemical; DNA, Neoplasm; Humans; Hydrolysis; In Vitro Techniques; Leukemia L1210; Mouth Neoplasms; Nucleosides; Phosphates; Pyrimidines; Pyrroles; RNA, Neoplasm; Thymidine; Tritium; Uridine | 1971 |